Regenerative Procedure Comparisons: Placebo, Standard Care, and Follow-Up

By the Regenerative Evidence Guide Team

What “Compared to Placebo” and “Compared to Standard Care” Actually Mean

When you’re researching a regenerative medicine procedure — stem cell injections, PRP (platelet-rich plasma), exosome therapy, or similar — you’ll often see claims like “shown effective in clinical studies.” That phrase can hide a lot. A study that compares a procedure to placebo (a fake or inactive treatment) is answering a different question than one that compares it to standard care (the current, established treatment for a condition). Knowing which comparison a study used — and what happened at follow-up — is often the single most useful thing you can check before taking a claim at face value. For general background on how studies are designed and reported, ClinicalTrials.gov’s Learn About Studies page is a useful starting point.

The Three Comparisons You’ll See, and What Each One Tells You

• Placebo-controlled: One group gets the real procedure; another gets a fake version (a sham injection, for example) that looks and feels similar. This design helps separate the treatment’s actual biological effect from the effect of simply receiving attention, an injection, or believing you’re being treated — known as the placebo response. It does not tell you how the procedure compares to treatments you could already get.
• Standard-of-care comparison: One group gets the new procedure; another gets the current established treatment (physical therapy, an approved medication, a conventional surgery, etc.). This design tells you whether the new procedure performs better, worse, or about the same as what’s already available — which is usually the more practically useful question for a patient deciding between options.
• No comparison group (single-arm or “case series”): Everyone in the study gets the procedure, and researchers track what happens. This design can generate early signals but cannot, on its own, tell you whether people would have improved anyway, or how much of the result is a placebo response. Claims based only on this kind of study deserve extra scrutiny.

Myth vs. Reality: Common Regenerative Medicine Claims

• Myth: “It’s listed on ClinicalTrials.gov, so it’s FDA-approved.” Reality: Registering a study on ClinicalTrials.gov does not mean a product is FDA-approved or legally marketed. The FDA has specifically warned that some clinics point patients to a ClinicalTrials.gov listing to imply regulatory compliance that doesn’t exist.
• Myth: “If people in the study got better, the treatment worked.” Reality: Many conditions naturally improve or fluctuate over time regardless of treatment. Without a comparison group, it’s difficult to know how much of the improvement is due to the procedure itself.
• Myth: “It’s made from my own cells (or donated tissue), so it’s automatically safe.” Reality: The FDA has documented safety concerns with unapproved regenerative products—including those from a person’s own body—such as infections, unwanted tissue growth, and reactions at the injection site, when these products haven’t undergone required safety review.
• Myth: “A short follow-up period (a few weeks) proves lasting benefit.” Reality: Short follow-up can miss both delayed complications and the fading of an early placebo response. Longer, pre-planned follow-up gives a more reliable picture of durability.

Where the Evidence Runs Out

Even a well-designed comparison study has limits worth knowing before you rely on it:

• A single study — even a well-designed one — is rarely the final word. Researchers generally look for the same result to be replicated across multiple independent studies before treating a finding as reliable.
• Results in one condition (for example, knee osteoarthritis) don’t automatically apply to a different condition, even if both are described as “joint pain” or “regenerative.”
• Study populations matter. A study conducted in younger, healthier participants may not reflect outcomes for someone older or with other health conditions.
• Some regenerative products currently being marketed to consumers have not gone through the FDA’s required review process at all — meaning there is no independently verified safety or effectiveness data behind the claims being made about them.

A Conversation Worksheet: Questions to Bring to Your Provider

These questions are designed to help you evaluate what you’re being told — not to diagnose your condition or choose a treatment for you.

1. About the evidence: “Is this procedure supported by a study that compared it to placebo, to standard treatment, or to nothing at all?”
2. About regulatory status: “Has this specific product received FDA approval or clearance, or is it being offered under an active Investigational New Drug (IND) application?”
3. About follow-up: “How long were people followed after treatment in the studies you’re citing, and what happened to results over that time?”
4. About risk: “What are the documented risks for this specific procedure, and how are complications monitored and reported?”
5. About alternatives: “What would happen if I chose standard care instead, or waited?”

For broader guidance on weighing evidence like this before your appointment, see our Start Here guide.

Red Flags That Warrant Extra Caution

The FDA has specifically warned that unapproved regenerative products marketed outside of an active clinical trial have been linked to serious harms, including blindness, tumor formation, neurological events, and life-threatening infections. If you experience a new or worsening symptom after a regenerative procedure—vision changes, signs of infection, or a new neurological symptom—contact your treating provider promptly, and use local emergency services for any symptom that feels urgent or severe.

If you believe you’ve been offered a product outside a legitimate clinical trial, or you want to report a bad outcome, the FDA accepts reports at ocod@fda.hhs.gov, and adverse events specifically can be reported through the FDA’s MedWatch program.

A Note on Where This Guide Fits

Regenerative Evidence Guide is an independent educational publication. We are not affiliated with any regenerative medicine academy, training program, conference, faculty, or clinical practice that may have previously used this domain, and we do not provide treatment, medical advice, or continuing education credit. Our role is to help readers understand how to evaluate the evidence behind regenerative medicine claims so they can ask better-informed questions of their own care team. For more on how we vet the sources behind articles like this one, see How We Research and Use Sources.

Medical Disclaimer

This article is for general educational purposes only and is not medical advice. It is not a substitute for a diagnosis, treatment recommendation, or consultation with a qualified health care provider. Do not start, stop, or change any treatment based on this article. If you have a medical emergency, contact local emergency services immediately.

By Regenerative Evidence Guide Editorial Team. Sources: U.S. Food and Drug Administration, “Important Patient and Consumer Information About Regenerative Medicine Therapies” (content current as of April 8, 2024); ClinicalTrials.gov, “Learn About Studies.” Last updated: September 23, 2026.